Skip to main content
logo
Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.585
-0.085 (-1.82%)
Aug 12, 2026, 1:58 PM EDT - Market open

Arbutus Biopharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
181.7214.086.1718.1439.0210.99
Revenue Growth
1078.78%128.21%-65.98%-53.51%255.11%58.92%
Gross Profit
181.7214.086.1718.1439.0210.99
Operating Income
149-38.16-76.32-78.1-65.46-73.52
Net Income
153.05-33.5-69.92-72.85-69.46-88.39
Earnings Per Share
0.79-0.17-0.38-0.44-0.46-0.83
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
92.6391.47122.62126146.91155.32
Total Debt
3.634.196.128.7212.5518.91
Net Cash (Debt)
8987.28116.51117.28134.36136.41
Net Cash Growth
-4.39%-25.08%-0.66%-12.71%-1.50%35.42%
Net Cash Per Share
0.460.460.630.710.891.28

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-24.63-39.64-64.85-85.94-35.36-67.53
Capital Expenditures
---0.18-1.01-0.51-0.81
Free Cash Flow
-24.63-39.64-65.03-86.94-35.87-68.34
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
81.99%-270.96%-1236.74%-430.53%-167.75%-669.11%
Pretax Margin
84.23%-237.88%-1133.04%-401.57%-166.62%-693.91%
Profit Margin
84.23%-237.88%-1133.04%-401.57%-178.01%-693.91%
FCF Margin
-13.55%-281.45%-1053.83%-479.27%-91.92%-621.96%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-236.87236.87236.87236.87236.87
PS Ratio
4.8565.76100.6623.419.4051.33